ARTV
NASDAQArtiva Biotherapeutics Inc.
News · 26 weeks570%
2026-03-012026-08-23
Mix2790d
- Insider11(41%)
- Other10(37%)
- SEC Filings6(22%)
Latest news
25 items- INSIDERChief Medical Officer Banerjee Subhashis exercised 429 shares at a strike of $1.92 and sold $5,148 worth of shares (429 units at $12.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
- SECSEC Form EFFECT filed by Artiva Biotherapeutics Inc.EFFECT - Artiva Biotherapeutics, Inc. (0001817241) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Artiva Biotherapeutics Inc.SCHEDULE 13G/A - Artiva Biotherapeutics, Inc. (0001817241) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Artiva Biotherapeutics Inc.SCHEDULE 13G/A - Artiva Biotherapeutics, Inc. (0001817241) (Subject)
- SECSEC Form S-3 filed by Artiva Biotherapeutics Inc.S-3 - Artiva Biotherapeutics, Inc. (0001817241) (Filer)
- SECSEC Form 10-Q filed by Artiva Biotherapeutics Inc.10-Q - Artiva Biotherapeutics, Inc. (0001817241) (Filer)
- SECArtiva Biotherapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Artiva Biotherapeutics, Inc. (0001817241) (Filer)
- PRArtiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business HighlightsClinical, safety and translational data presented at EULAR 2026 reinforced AlloNK®’s potential to drive deep B-cell depletion and meaningful clinical activity, with a tolerability profile supportive of outpatient administration U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to AlloNK plus rituximab for refractory rheumatoid arthritis (RA) Initiating Phase 3 registrational randomized controlled trial evaluating AlloNK plus rituximab versus rituximab alone in approximately 150 refractory RA patients in the second half of 2026 Strong balance sheet with cash, cash equivalents and investments of $349.4 million a
- SECSEC Form DEF 14A filed by Artiva Biotherapeutics Inc.DEF 14A - Artiva Biotherapeutics, Inc. (0001817241) (Filer)
- INSIDERDirector Ra Capital Management, L.P. bought $455,726 worth of shares (45,768 units at $9.96) (SEC Form 4)4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
- INSIDERDirector Ra Capital Management, L.P. bought $412,777 worth of shares (41,319 units at $9.99) (SEC Form 4)4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Artiva Biotherapeutics Inc.SCHEDULE 13D/A - Artiva Biotherapeutics, Inc. (0001817241) (Subject)
- INSIDERDirector Ra Capital Management, L.P. bought $2,583,314 worth of shares (264,586 units at $9.76) (SEC Form 4)4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
- INSIDERAmendment: Director Ra Capital Management, L.P. bought $58,307 worth of shares (6,522 units at $8.94) (SEC Form 4)4/A - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
- SECSEC Form 8-K filed by Artiva Biotherapeutics Inc.8-K - Artiva Biotherapeutics, Inc. (0001817241) (Filer)
- INSIDERDirector Ra Capital Management, L.P. bought $1,432,119 worth of shares (160,354 units at $8.93) (SEC Form 4)4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
- PRArtiva Biotherapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN DIEGO, July 17, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that the Compensation Committee of its Board of Directors approved new employee inducement grants covering an aggregate of 288,800 restricted stock units (the "Inducement Grants") for 17 new employees. The Inducement Grants were granted pursuant to Artiva’s 2025 Inducement Plan (the "Inducement Plan"), and were effective July 14, 2026. The Inducement Grants will vest over four years, with vesting aligned to quarterly vestin
- INSIDERDirector Ra Capital Management, L.P. bought $194,040 worth of shares (21,654 units at $8.96) (SEC Form 4)4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
- INSIDERDirector Ra Capital Management, L.P. bought $292,126 worth of shares (32,876 units at $8.89) (SEC Form 4)4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
- PRArtiva Biotherapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual ConferenceSAN DIEGO, June 23, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that Artiva management will participate in a fireside chat at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on Tuesday, June 30, 2026, at 3:30 pm EDT. To access the audio webcast and subsequent archived recording of this and other company presentations, please visit the Investors section of Artiva’s website. The archived audio webcast will remain available for replay on Artiva’s website for 90 days. About
- INSIDERDirector Ra Capital Management, L.P. bought $4,599,903 worth of shares (531,326 units at $8.66) (SEC Form 4)4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Artiva Biotherapeutics Inc.SCHEDULE 13D/A - Artiva Biotherapeutics, Inc. (0001817241) (Subject)
- INSIDERDirector Ra Capital Management, L.P. bought $7,650,148 worth of shares (1,027,722 units at $7.44) (SEC Form 4)4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
- PRArtiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast TodayMultiple EULAR presentations reinforce potential of AlloNK to drive deep B-cell depletion and meaningful clinical responses across refractory rheumatoid arthritis, Sjögren disease and systemic sclerosisLate-breaking oral presentation highlighted robust clinical responses with AlloNK plus rituximab across 31 patients with rheumatologic diseasesRheumatoid arthritis data showed clinically meaningful responses in highly refractory patients, including 71% ACR50 response at six months in the company-sponsored Phase 2a basket trialSafety and translational data support AlloNK's potential as an outpatient-administered, community-compatible deep B-cell depleting therapyU.S. Food and Drug Administratio
- PRThe $13 Million Company Teaching the Immune System to Hunt CancerIssued on behalf of GT Biopharma, Inc. (NASDAQ:GTBP)Three drugs in human trials. A platform licensed from one of the world's top cancer-research universities. A market cap smaller than a Manhattan apartment. For investors willing to look where almost no one is looking, GT Biopharma is the kind of asymmetric setup that biotech is built on.NEW YORK, May 29, 2026 /CNW/ -- USA News Group Market Commentary - Start with the number that makes everyone do a double take. As of mid-May 2026, GT Biopharma (NASDAQ:GTBP) carried a market capitalization of roughly $13 million. Thirteen million. That is not a typo, and it is not a shell company. It is a clinical-stage immuno-oncology company with three sep
ARTV FAQ
6 questionsWhere does ARTV stock trade?
Artiva Biotherapeutics Inc. (ARTV) is listed on NASDAQ.What sector and industry is ARTV in?
Artiva Biotherapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Artiva Biotherapeutics Inc. go public?
Artiva Biotherapeutics Inc. (ARTV) completed its IPO in 2024.What are analysts saying about ARTV?
Artiva Biotherapeutics Inc. has had 7 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $1200.00 price target on 2025-06-11. Recent price targets range from $1200.00 to $2300.00.What companies are similar to ARTV?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare ARTV side-by-side with any of them on Quantisnow.How can I track ARTV on Quantisnow?
Quantisnow aggregates Artiva Biotherapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ARTV to receive live email and push alerts on every new disclosure.